Press release
Myotonic Dystrophy Drug Market Size | COVID-19 Impact Analysis | Forecast to 2028
The global myotonic dystrophy drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Myotonic dystrophy is a muscular dystrophy caused by a long-term genetic mutation. It is the most common type of muscular dystrophy in adulthood, affecting roughly one out of every 8,000 people. Muscle atrophy and weakness worsen over time as a symptom. Muscles contract frequently and take a long time to relax. Some people have a relatively mild type, while others have a severe one that affects them from birth. This is owing to the condition's molecular foundation, which is caused by a dynamic mutation called a triplet repeat expansion, which occurs when three base pairs of DNA are present in varied copies numbers.To Request a Sample of our Report on Myotonic Dystrophy Drug Market: https://www.omrglobal.com/request-sample/myotonic-dystrophy-drug-market
The primary factor propelling the growth of global myotonic dystrophy market is the introduction of novel disease therapeutics and increased R&D activities. For instance, in November 2021, Locanabio, Inc., a genetic pharmaceuticals business focused on developing therapies for patients with severe neuromuscular, neurodegenerative, and retinal illnesses, announced new preclinical data from its myotonic dystrophy type 1 (DM1) program. Locanabio scientists used their CORRECTx platform to show a dose-dependent reduction in toxic CUG foci in both DM1 patient muscle cells and a preclinical mouse model of DM1, which resulted in an alternative RNA splicing correction and a statistically significant reduction in myotonia, or muscle weakness. Further, in April 2020, Scientists from the University's Schools of Life Sciences and Chemistry have discovered that inhibiting a molecule in patients' cells called CDK12 can potentially develop a therapy to alleviate some of the symptoms and support treat this incurable condition.
Some major key players in the market include Isis Pharmaceuticals, Inc., and Lupin Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, AOC 1001 has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of myotonic dystrophy type 1 (DM1). AOC 1001 is a monoclonal antibody that binds to transferrin receptor 1 and is coupled to a short interfering RNA that targets DMPK mRNA. AOC 1001 is expected to address the fundamental cause of DM1 by lowering DMPK mRNA levels in skeletal, cardiac, and smooth muscle. Data from preclinical tests back up the designation, showing that AOC 1001 successfully transported the small interfering RNA to muscle cells, resulting in dose-dependent decreases in DMPK mRNA.
Market Coverage
· The market number available for - 2021-2028
· Base year- 2021
· Forecast period- 2022-2028
Segment Covered-
· By Type
· By Application
Regions Covered-
· North America
· Europe
· Asia-Pacific
· Rest of the World
Competitive Landscape- Isis Pharmaceuticals, Inc., and Lupin Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Myotonic Dystrophy Drug MarketReceiver is Available @ https://www.omrglobal.com/industry-reports/myotonic-dystrophy-drug-market
Global Myotonic Dystrophy Drug Market Report by Segment
By Type
· Myotonic Dystrophy Type 1 (DM1)
· Myotonic Dystrophy Type 2 (DM2)
By Application
· Hospital
· Clinic
· Others
Global Myotonic Dystrophy Drug Market Report by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
· Latin America
· Middle East & Africa
Reasons to buy from us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myotonic Dystrophy Drug Market Size | COVID-19 Impact Analysis | Forecast to 2028 here
News-ID: 2584519 • Views: …
More Releases from Orion Market Research

Hair Accessories Market Poised for Strong Growth Driven by Gen Z Trends and Sust …
Hair accessories market was valued at $23.8 billion in 2024 and is projected to reach $55.2 billion in 2035, growing at a CAGR of 8.2% during the forecast period (2025-2035). Generation Z, with significant disposable income, is transforming the hair accessories category in a major way. Their close connection to trends creates a unique feeling of urgency to self-express through fashion, such as clips, scrunchies, and barrettes. It has become…

Railway Management System Market Size Analysis, Competitive Insights, Leading Pl …
Railway System (or Railway Management System) market was valued at approximately USD 28.28 billion, and it is expected to reach about USD 45.19 billion by 2033, growing at a CAGR of around 4.8% from 2024 to 2033.
Railway Management System Market Overview
The Railway Management System market includes technologies and systems used to plan, monitor, and manage railway operations-everything from traffic and signaling systems to asset and maintenance management, passenger information,…

Monocalcium Phosphate Market Size Analysis, Competitive Insights, Leading Player …
Monocalcium Phosphate market was valued at about USD 4.2 billion, and it is anticipated to reach around USD 6.9 billion by 2033, growing at a CAGR of approximately 5% from 2023 to 2033.
Monocalcium Phosphate Market Overview
Monocalcium phosphate (MCP) is a calcium-phosphorus compound widely used in animal feed, fertilizers, and also in food and beverage applications (for example as leavening agent or acidity regulator), due to its solubility and bioavailability. The…

Automotive Lubricants Market Size Analysis, Competitive Insights, Leading Player …
Automotive Lubricants Market was valued at approximately USD 70.44 billion. By 2033, it is expected to reach around USD 107.09 billion, growing at a CAGR of about 3.3% from 2025 to 2033.
Automotive Lubricants Market Overview
The automotive lubricants market consists of products like engine oils, gear oils, greases, hydraulic fluids, and transmission fluids that reduce friction, wear and tear, and improve efficiency and lifespan of vehicle components. Demand is driven by…
More Releases for Myotonic
Myotonic Dystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Myotonic dystrophy (DM) is one of the most common forms of adult-onset muscular dystrophy, characterized by progressive muscle weakness, myotonia, cardiac issues, respiratory complications, and cognitive impairment. It is caused by genetic mutations-most often in the DMPK gene (DM1) or the CNBP gene (DM2)-leading to toxic RNA repeats that disrupt normal cellular function.
Despite being a rare neuromuscular disorder, myotonic dystrophy presents significant unmet needs, as there is currently no cure…
UK Myotonic Dystrophy Drug Market Segments |Latest Innovations & Demands
"Detailed Study of Myotonic Dystrophy Drug Market (2024-2032)
New Analysis Of Myotonic Dystrophy Drug Market overview, spend analysis, imports, segmentation, key players and opportunity analysis 2024-2032. The study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.
It also provides a snapshot of the country's economy and Industry outlook. It provides…
Myotonic Dystrophy Medication Market Business Growth, Trends, and Challenges by …
A New report from the WGR, titled Myotonic Dystrophy Medication Market Report 2024 Market Size, Trends, and Global Forecast 2024-2032, offers a thorough analysis of the market's changing trends, investment opportunities, and competitive landscape. By the end of 2032, the Myotonic Dystrophy Medication market trends will be valued at USD 1.1, per a WGR analysis. Furthermore, the report projects that the Myotonic Dystrophy Medication market trends will grow at a…
Myotonic Dystrophy Market Size, Epidemiology, Analysis & Trends 2023-2033
Myotonic Dystrophy Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
Myotonic Dystrophy Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 …
DelveInsight's, "Myotonic Dystrophy Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myotonic Dystrophy Pipeline…
Emerging Trends in the 2022-2029 Myotonic Dystrophy Medication Market
Global Industrial aspects of Myotonic Dystrophy Medication Sales Market 2023-2029: The global Myotonic Dystrophy Medication Market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Myotonic Dystrophy Medication is estimated to increase from $ million in…